ProCE Banner Activity

CE / CME

Targeting LAG-3 to Potentiate Antitumor Immune Activity: Expert Guidance on Molecular Function and Clinical Application

Multimedia
Watch this on-demand webcast of a live webinar to gain expert insights on the safety and efficacy of anti–LAG-3 immunotherapies in the management of various solid tumors.

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Nurses: 0.75 Nursing contact hour

Released: April 20, 2022

Expiration: April 19, 2023

No longer available for credit.

Share

Faculty

Evan J. Lipson

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Tian Zhang

Tian Zhang, MD, MHS

Associate Professor
Genitourinary Oncology and Multi-Disease Precision Oncology Programs
Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Target Audience

This program is intended for medical oncologists, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with solid tumors.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explain the mechanism of action of LAG-3 inhibitors and the rationale for combining with other cancer treatment options
  • Describe emerging clinical trial evidence of the use of anti–LAG-3 immunotherapies across tumor types
  • Identify adverse events associated with anti–LAG-3 immunotherapies and combinations to implement supportive management strategies
  • Integrate new data into clinical practice and identify patients eligible for clinical trials

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Evan J. Lipson, MD, has disclosed that he has received consulting fees from Array BioPharma, Bristol-Myers Squibb, EMD Serono, Genentech, MacroGenics, Merck, Novartis, Odonate Therapeutics, Regeneron, and Sanofi and funds for research support paid to his institution from Bristol-Myers Squibb, Merck, Regeneron, and Sanofi.

Tian Zhang, MD, MHS

Associate Professor
Genitourinary Oncology and Multi-Disease Precision Oncology Programs
Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Tian Zhang, MD, MHS, has disclosed that she has received consulting fees from AbbVie/Stemcentrx, Amgen, Aptitude Health, Aravive, AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, Dendreon, Eisai, Exelixis, Genentech/Roche, Janssen, Merck, MJH Associates, Pfizer, QED Therapeutics, Seagen, and Vaniam Group and research support from AbbVie/Stemcentrx, AstraZeneca, Genentech/Roche, Janssen, Merck, Merrimack, Mirati Therapeutics, Novartis, Omniseq, PDGx, Pfizer, Regeneron, and Seagen.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Kayla Douglas, PharmD

Director of Pharmacy
Mississippi Center for Advanced Medicine
Madison, Mississippi

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN, has disclosed that she has received speaker fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Gilead Sciences, Lilly, Morphosys, Pfizer, and Regeneron.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Credit Designation

CCO designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-115-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 20, 2022, through April 19, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in understanding and applying the latest science and clinical trial data on current and emerging anti–LAG-3 immunotherapies across tumor types to clinical practice.